Are you above the legal age to view this content in your province/state?

Home / Industry News / Scientific evidence is beginning to mount that cannabis may prove beneficial in the fight against cancer

Scientific evidence is beginning to mount that cannabis may prove beneficial in the fight against cancer

Scientific evidence is beginning to mount that cannabis may prove beneficial in the fight against cancer

U.S., September 5, 2019 (GREENENTREPENEUR)- Scientific evidence is beginning to mount that cannabis may prove beneficial in the fight against cancer. The latest comes from a Harvard University study involving cannabis flavonoids and pancreatic cancer.

The news comes on the heels of other research the past several years that involves marijuana and cancer treatment. For example, a Washington study found that 25 percent of cancer patients surveyed used marijuana to manage pain from cancer treatments. Studies in Minnesota and Israel found that marijuana use lowered usage of pain-killing opioids, including those used by cancer patients.

The study from Harvard’s Dana-Farber Cancer Institute is different because it discovered cannabis might go beyond treatment for cancer-related pain and nausea. The study found that flavonoids in cannabis show potential in slowing pancreatic cancer tumor growth and stopping the spread of pancreatic cancer.

Related: We Are Nearing the End of Cannabis Prohibition

What are flavonoids, anyway?
Found throughout the plant kingdom, flavonoids are a natural chemical that gives plants their color. They contain vitamins and minerals and antioxidant properties. Each color offers something slightly different, which is why nutritionists recommend eating a diet with many differently colored fruits and vegetables.

In marijuana, these flavonoids are sometimes called cannflavin. In 1985, a London researcher found that cannflavin has the potential to fight inflammation and pain. Canadian researchers recently announced they have unlocked the key to using cannflavin for producing a natural painkiller 30 times more effective than aspirin.

But the Harvard study takes cannabis flavonoids into a whole new area.

Related: Honey, I Shrunk The Cannabis

Harvard study takes on pancreatic cancer.
Researchers at the Dana-Farber Cancer Institute announced in a study published in Frontiers in Oncology that cannabis flavonoids may have “significant therapy potential” in treating pancreatic cancer.

The group decided to focus on pancreatic cancer because it is so difficult to treat. They wrote that pancreatic cancer comes with a “five-year survival rate for patients at a dismal 8 percent.” One of the key factors in this is that pancreatic cancer creates an immunosuppressive tumor that develops a resistance to treatment.

Using cannabis flavonoids, the researchers created a drug called FBL-03G. This drug, when injected into mice and combined with radiotherapy, slowed cell growth of certain types of cancer. The drug also led to “significant increase in survival for animals with pancreatic cancer compared to control cohorts.”

Wilfred Ngwa, Global Health Director at Dana-Farber Cancer Institute and Brigham and Women’s Cancer Center at Harvard Medical School, told survivor.net that the findings were “very surprising.” The researchers hope to eventually get the drug approved for a clinical trial.

The findings by the Harvard researchers add to a growing list of studies showing there is potential for marijuana in battling at least the spread of cancer. A recent study out of India reviewed the literature from studies around the world. Among their findings were studies that showed evidence cannabis can slow cancer tumor growth and that one CBD compound showed potential in stopping the spread of certain types of breast cancer.

Disclaimer

Investment Value Finders specializes in providing opinions and information on stocks to individuals who wish to receive them. Our reports are construed for information purposes solely and are distributed free of charge to individuals who wish to receive them.


Investment Value Finders does not promote, condone or advocate licit or illicit drug use. Investment Value Finders cannot be held responsible for materials or contests posted on its website pages, or pages to which we provide links, which promote, condone or advocate licit or illicit drug use or illegal activities.


DO NOT BASE ANY INVESTMENT DECISION UPON ANY MATERIALS FOUND ON THIS WEBSITE. We are not registered as a securities broker-dealer or an investment adviser. We are neither licensed nor qualified to provide investment advice.


Investment Value Finders occasionally receives direct compensation for hosting links (or other* advertisements) to third party content that may be subject to disclaimer pursuant to Section 17(b) of the Securities Act of 1933. For those instances where the link text contains company or stock-specific mention, we provide the following list of compensation received in order to ensure full disclosure and transparency.


Investment Value Finders is intended for those 21+ years of age only!

Check Also

FSD Pharma Talks About Their Expanding Revenue Potential

FSD Pharma Talks About Their Expanding Revenue Potential

Phoenix, Arizona–(Newsfile Corp. – September 12, 2019) – The Stock Day Podcast welcomed FSD Pharma …